Convalescent plasma therapy carries the risk of allergic reactions, lung damage and difficulty breathing, and transmission of infections. "In a group of about 3,000 patients, researchers compared the mortality of patients who received plasma with high and low levels, of antibodies at different stages of illness. Of people who got plasma with high levels of antibodies, 8.9 percent died, on average, after seven days of treatment. That’s compared with the 13.7 percent of people who got plasma with low levels of antibodies who died in that time frame." Last week, the US Food and Drug Administration on Wednesday put on hold emergency authorization for blood plasma as a Covid-19 treatment, according to the NY Times.

Source: The Star August 26, 2020 08:48 UTC